交易 Protagonist Therapeutics, Inc. - PTGX CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
价差 | 0.08 | ||||||||
多头隔夜费
Long position overnight fee
前往平台 | -0.026151% | ||||||||
空头隔夜费
Short position overnight fee
前往平台 | 0.003929% | ||||||||
隔夜费时间 | 21:00 (UTC) | ||||||||
最小交易量 | 1 | ||||||||
货币 | USD | ||||||||
保证金 | 5% | ||||||||
上市交易所 | United States of America | ||||||||
交易费 | 0% |
*Information provided by Capital.com
Protagonist Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | 平仓 | Change | Change (%) | 開倉 | High | Low |
---|---|---|---|---|---|---|
Sep 26, 2023 | 17.45 | 0.29 | 1.69% | 17.16 | 18.14 | 17.16 |
Sep 25, 2023 | 17.17 | 0.38 | 2.26% | 16.79 | 17.17 | 16.37 |
Sep 22, 2023 | 17.08 | 0.53 | 3.20% | 16.55 | 17.12 | 16.52 |
Sep 21, 2023 | 16.92 | 0.16 | 0.95% | 16.76 | 17.01 | 16.49 |
Sep 20, 2023 | 16.97 | -0.43 | -2.47% | 17.40 | 17.75 | 16.92 |
Sep 19, 2023 | 17.63 | 0.15 | 0.86% | 17.48 | 17.87 | 17.42 |
Sep 18, 2023 | 17.60 | -0.11 | -0.62% | 17.71 | 17.97 | 17.54 |
Sep 15, 2023 | 17.85 | -0.12 | -0.67% | 17.97 | 18.03 | 17.32 |
Sep 14, 2023 | 17.95 | -0.27 | -1.48% | 18.22 | 18.59 | 17.82 |
Sep 13, 2023 | 18.41 | -0.06 | -0.32% | 18.47 | 18.84 | 18.39 |
Sep 12, 2023 | 18.78 | 0.05 | 0.27% | 18.73 | 19.11 | 18.63 |
Sep 11, 2023 | 18.83 | -0.12 | -0.63% | 18.95 | 18.99 | 18.58 |
Sep 8, 2023 | 19.00 | 0.53 | 2.87% | 18.47 | 19.07 | 18.47 |
Sep 7, 2023 | 18.70 | -0.82 | -4.20% | 19.52 | 19.53 | 18.69 |
Sep 6, 2023 | 19.75 | 0.39 | 2.01% | 19.36 | 19.79 | 19.10 |
Sep 5, 2023 | 19.54 | 0.03 | 0.15% | 19.51 | 19.85 | 19.12 |
Sep 1, 2023 | 19.49 | -0.34 | -1.71% | 19.83 | 20.18 | 19.41 |
Aug 31, 2023 | 19.78 | 0.30 | 1.54% | 19.48 | 20.26 | 19.48 |
Aug 30, 2023 | 19.89 | -0.09 | -0.45% | 19.98 | 20.26 | 19.58 |
Aug 29, 2023 | 20.20 | 0.23 | 1.15% | 19.97 | 20.43 | 19.97 |
Protagonist Therapeutics, Inc. Events
时间(协调世界时) (UTC) | 国家 | 事件 |
---|---|---|
Monday, November 6, 2023 | ||
时间(协调世界时) (UTC) 10:59 | 国家 US
| 事件 Q3 2023 Protagonist Therapeutics Inc Earnings Release Q3 2023 Protagonist Therapeutics Inc Earnings ReleaseForecast(预报) -上一页 - |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
总收入 | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 |
总营业费用 | 157.954 | 153.202 | 93.729 | 80.752 | 73.194 |
销售/一般/行政费用,总计 | 31.739 | 27.196 | 18.638 | 15.749 | 13.697 |
研究与开发 | 126.215 | 126.006 | 74.506 | 65.003 | 59.497 |
营业收入 | -131.373 | -125.845 | -65.101 | -80.521 | -42.269 |
利息收入(费用),非经营净值 | 4.06 | 0.443 | 0.302 | 2.644 | 2.546 |
其他,净值 | -0.08 | -0.149 | -0.046 | -0.001 | 0 |
税前净收入 | -127.393 | -125.551 | -64.845 | -77.878 | -39.723 |
税后净收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
未计算非常项目前的净收益 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
净收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
Total Adjustments to Net Income | 0 | ||||
普通股股东可获收益 (不含非经常性项目) | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
普通股股东可获收益 (含非經常性項目) | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
摊薄净收入 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
摊薄后加权平均股 | 49.0422 | 46.3229 | 34.3965 | 25.894 | 22.3645 |
扣除特别项目的每股摊薄盈利 | -2.59762 | -2.71034 | -1.92316 | -2.98088 | -1.74044 |
每股正常摊薄盈利 | -2.59762 | -2.71034 | -1.91211 | -2.98088 | -1.74044 |
收入 | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 |
非常规项目总计 | |||||
Dividends per Share - Common Stock Primary Issue | 0 | ||||
异常费用(收入) | 0 | 0 | 0.585 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
总收入 | 0 | 0 | 0 | 0 | 0.859 |
收入 | 0 | 0 | 0 | 0 | 0.859 |
总营业费用 | 42.354 | 36.021 | 36.516 | 32.303 | 42.302 |
销售/一般/行政费用,总计 | 9.172 | 8.605 | 6.632 | 6.901 | 7.691 |
研究与开发 | 33.182 | 27.416 | 29.884 | 25.402 | 34.611 |
营业收入 | -42.354 | -36.021 | -36.516 | -32.303 | -41.443 |
利息收入(费用),非经营净值 | 3.913 | 2.491 | 2.251 | 1.157 | 0.484 |
其他,净值 | -0.019 | -0.195 | 0.071 | -0.086 | -0.078 |
税前净收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
税后净收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
未计算非常项目前的净收益 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
净收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
普通股股东可获收益 (不含非经常性项目) | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
普通股股东可获收益 (含非經常性項目) | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
摊薄净收入 | -38.46 | -33.725 | -34.194 | -31.232 | -41.037 |
摊薄后加权平均股 | 56.7757 | 50.5737 | 49.2549 | 49.1076 | 49.0499 |
扣除特别项目的每股摊薄盈利 | -0.6774 | -0.66685 | -0.69422 | -0.63599 | -0.83664 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
每股正常摊薄盈利 | -0.6774 | -0.66685 | -0.69422 | -0.63599 | -0.83664 |
异常费用(收入) | 0 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
流动资产总额 | 243.077 | 340.736 | 315.606 | 145.311 | 137.503 |
现金和短期投资 | 237.355 | 326.9 | 305.809 | 133.017 | 128.853 |
现金等价物 | 125.744 | 123.665 | 117.358 | 33.006 | 82.233 |
短期投资 | 111.611 | 203.235 | 188.451 | 100.011 | 46.62 |
应收账款总额,净额 | 0.052 | 5.333 | 3.821 | 7.499 | 6.511 |
預付的費用 | 5.67 | 8.503 | 5.966 | 4.785 | 2.129 |
其他流動資産,總計 | 0.01 | 0.01 | 0.01 | ||
總資産 | 247.928 | 347.695 | 324.468 | 154.917 | 139.472 |
物業/廠房/設備,總計 - 淨額 | 4.626 | 6.734 | 6.412 | 7.723 | 0.861 |
物業/廠房/設備,總計 - 總額 | 9.88 | 10.992 | 9.885 | 10.364 | 2.938 |
累計折舊,總計 | -5.254 | -4.258 | -3.473 | -2.641 | -2.077 |
長期投資 | 2 | ||||
其他長期資産,總計 | 0.225 | 0.225 | 0.45 | 1.883 | 1.108 |
流動負債總額 | 31.179 | 44.016 | 40.241 | 35.406 | 26.158 |
應付賬款 | 3.64 | 1.6 | 3.075 | 2.79 | 5.711 |
Payable/Accrued | |||||
預提費用 | 27.055 | 39.509 | 19.875 | 13.494 | 11.068 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
負債總額 | 32.32 | 47.674 | 44.862 | 74.953 | 26.957 |
長期債務總額 | 0 | 0 | 0 | 9.794 | 0 |
長期債務 | 0 | 9.794 | |||
總權益 | 215.608 | 300.021 | 279.606 | 79.964 | 112.515 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
普通股 | 0.00049 | 0.00048 | 0.00044 | 0.00027 | 0 |
額外實收資本 | 752.722 | 709.682 | 563.389 | 297.846 | 253.222 |
留存收益(累計赤字) | -536.755 | -409.362 | -283.811 | -217.661 | -140.474 |
其他權益,總計 | -0.35949 | -0.29948 | 0.02756 | -0.22127 | -0.233 |
總負債和股東權益 | 247.928 | 347.695 | 324.468 | 154.917 | 139.472 |
已發行普通股總數 | 49.3392 | 47.8383 | 43.7455 | 27.2176 | 23.1872 |
其他流動負債,總計 | 0.484 | 2.907 | 17.291 | 19.122 | 9.379 |
其他負債,總計 | 1.141 | 3.658 | 4.621 | 29.753 | 0.799 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
流动资产总额 | 235.736 | 243.077 | 276.617 | 304.302 | 341.522 |
现金和短期投资 | 230.759 | 237.355 | 267.437 | 291.89 | 305.289 |
现金等价物 | 127.686 | 125.744 | 152.816 | 120.237 | 98.477 |
短期投资 | 103.073 | 111.611 | 114.621 | 171.653 | 206.812 |
应收账款总额,净额 | 0.051 | 0.052 | 0.62 | 3.363 | 28.504 |
預付的費用 | 4.926 | 5.67 | 8.56 | 9.049 | 7.729 |
總資産 | 239.858 | 247.928 | 282.174 | 310.512 | 348.296 |
物業/廠房/設備,總計 - 淨額 | 3.897 | 4.626 | 5.332 | 5.985 | 6.549 |
長期投資 | |||||
其他長期資産,總計 | 0.225 | 0.225 | 0.225 | 0.225 | 0.225 |
流動負債總額 | 23.229 | 31.179 | 36.754 | 40.088 | 43.456 |
應付賬款 | 4.021 | 3.64 | 4.715 | 1.412 | 7.159 |
預提費用 | 18.852 | 27.055 | 31.816 | 38.336 | 34.995 |
應付票據/短期債務 | 0 | 0 | 0 | 0 | 0 |
其他流動負債,總計 | 0.356 | 0.484 | 0.223 | 0.34 | 1.302 |
負債總額 | 23.691 | 32.32 | 38.558 | 42.534 | 46.518 |
長期債務總額 | 0 | 0 | 0 | 0 | 0 |
其他負債,總計 | 0.462 | 1.141 | 1.804 | 2.446 | 3.062 |
總權益 | 216.167 | 215.608 | 243.616 | 267.978 | 301.778 |
普通股 | 0.001 | 0.00049 | 0.00049 | 0.00049 | 0.00049 |
額外實收資本 | 786.768 | 752.722 | 746.657 | 740.027 | 732.542 |
留存收益(累計赤字) | -570.48 | -536.755 | -502.561 | -471.329 | -430.292 |
其他權益,總計 | -0.122 | -0.35949 | -0.48049 | -0.72049 | -0.47249 |
總負債和股東權益 | 239.858 | 247.928 | 282.174 | 310.512 | 348.296 |
已發行普通股總數 | 51.4405 | 49.3392 | 49.1984 | 48.6839 | 48.5521 |
其他流動資産,總計 | |||||
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
物業/廠房/設備,總計 - 總額 | 9.389 | 9.88 | 10.302 | 10.721 | 11.074 |
累計折舊,總計 | -5.492 | -5.254 | -4.97 | -4.736 | -4.525 |
- 年度
- 每季度
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
净收入/起跑线 | -127.393 | -125.551 | -66.15 | -77.187 | -38.924 |
经营活动产生的现金 | -108.137 | -107.865 | -72.484 | -41.527 | -49.947 |
经营活动产生的现金 | 1.034 | 0.813 | 0.789 | 0.703 | 0.527 |
非现金物品 | 25.988 | 20.187 | 10.455 | 9.588 | 7.125 |
营运资金的变化 | -7.766 | -3.314 | -19.016 | 26.144 | -18.017 |
投资活动产生的现金 | 91.468 | -15.86 | -90.965 | -53.71 | 2.213 |
资本支出 | -0.795 | -1.101 | -0.471 | -0.967 | -0.486 |
其他投资现金流量项目,总计 | 92.263 | -14.759 | -90.494 | -52.743 | 2.699 |
融资活动产生的现金 | 18.838 | 129.923 | 247.626 | 46.036 | 24.115 |
股票的发行(报废),净额 | 19.001 | 130.112 | 258.164 | 36.271 | 24.115 |
外汇效应 | -0.09 | -0.126 | 0.175 | -0.026 | -0.177 |
现金净变化 | 2.079 | 6.072 | 84.352 | -49.227 | -23.796 |
Deferred Taxes | 0 | 1.438 | -0.775 | -0.658 | |
Cash Taxes Paid | 0 | 0 | 0.438 | 0.07 | |
债务的发行(退还),净额 | 0 | -10.524 | 9.765 | ||
融资现金流项目 | -0.163 | -0.189 | -0.014 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -33.725 | -127.393 | -93.199 | -61.967 | -20.93 |
Cash From Operating Activities | -34.347 | -108.137 | -76.502 | -51.301 | -37.666 |
Cash From Operating Activities | 0.248 | 1.034 | 0.778 | 0.508 | 0.249 |
Non-Cash Items | 7.107 | 25.988 | 20.806 | 14.362 | 6.877 |
Changes in Working Capital | -7.977 | -7.766 | -4.887 | -4.204 | -23.862 |
Cash From Investing Activities | 9.826 | 91.468 | 87.533 | 30.258 | -4.476 |
Capital Expenditures | -0.01 | -0.795 | -0.725 | -0.563 | -0.273 |
Other Investing Cash Flow Items, Total | 9.836 | 92.263 | 88.258 | 30.821 | -4.203 |
Cash From Financing Activities | 26.463 | 18.838 | 18.285 | 17.605 | 16.925 |
Financing Cash Flow Items | -0.1 | -0.163 | -0.163 | -0.161 | -0.186 |
Issuance (Retirement) of Stock, Net | 26.563 | 19.001 | 18.448 | 17.766 | 17.111 |
Foreign Exchange Effects | 0 | -0.09 | -0.165 | 0.01 | 0.029 |
Net Change in Cash | 1.942 | 2.079 | 29.151 | -3.428 | -25.188 |
Deferred Taxes | 0 | ||||
Issuance (Retirement) of Debt, Net | 0 | ||||
Cash Taxes Paid | 0 |
交易计算器
如果您在特定日期(选择一个日期)开立差价合约交易并在不同日期(选择一个日期)关闭交易,计算您的假设盈亏。
交易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投资
交易规模(杠杆 x 投资):
開倉
平仓
做空 做多
Protagonist Therapeutics, Inc. Company profile
关于 Protagonist Therapeutics Inc.
Protagonist Therapeutics, Inc.是一家处于临床阶段的生物制药公司。 公司利用其多肽技术平台,发现和开发基于多肽的药物,以满足未满足的医疗需求。 其临床项目属于两类疾病,其中包括血液学和血液疾病,以及炎症和免疫调节疾病。 其主要的临床资产rusfertide(PTG-300)是一种注射用血色素模仿剂,正在开发用于治疗红细胞增多症、铁超载和其他血液疾病。 其其他临床资产PTG-943和PTG-200是正在开发的用于治疗炎症性肠病(IBD)的口服研究药物,旨在阻断已上市的可注射抗体药物的生物途径。 其PN-235和PN-232正在进行临床开发,是IL-R拮抗剂。 Protagonist Pty Limited是其子公司。
Industry: | Biotechnology & Medical Research (NEC) |
7707 Gateway Blvd Ste 140
NEWARK
CALIFORNIA 94560-1160
US
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗?
加入成为全球555,000万多名交易者的一份子,选择利用Capital.com进行交易吧。